SEC Comment Letter for Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259) (OTLC) — Sep 30, 2016
Oncotelic Therapeutics, Inc. (OTLC) (CIK 0000908259)
Date: Sept. 30, 2016 · CIK: 0000908259 · Accession: 0000000000-16-095386
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-21990
Letter
Mail Stop 4546 September 30, 2016 William D. Schwieterman Chief Executive Officer Mateon Therapeutics, Inc. 701 Gateway Blvd, Suite 210 South San Francisco, CA 94080
Re: Mateon Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 7, 2016 File No. 000-21990
Dear Dr. Schwieterman :
We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.
Sincerely,
/s/ Joseph McCann for
Show Raw Text
Mail Stop 4546 September 30, 2016 William D. Schwieterman Chief Executive Officer Mateon Therapeutics, Inc. 701 Gateway Blvd, Suite 210 South San Francisco, CA 94080 Re: Mateon Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed September 7, 2016 File No. 000-21990 Dear Dr. Schwieterman : We have completed our review of your filing . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities la ws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Joseph McCann for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Megan N. Gates, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.